Claritev (NYSE:CTEV) Issues Earnings Results, Beats Estimates By $5.45 EPS

by · The Cerbat Gem

Claritev (NYSE:CTEV – Get Free Report) announced its quarterly earnings results on Monday. The company reported $1.77 earnings per share for the quarter, beating analysts’ consensus estimates of ($3.68) by $5.45, FiscalAI reports. The company had revenue of $268.31 million during the quarter.

Here are the key takeaways from Claritev’s conference call:

  • Third-quarter revenue rose 9.1% year over year to $268.3 million and Adjusted EBITDA increased 4.4% to $162 million, exceeding expectations. Claritev raised its 2026 revenue, Adjusted EBITDA, and free cash flow guidance.
  • Bookings reached $27 million in Q3 and topped $100 million year to date; the company now expects $115 million–$125 million for 2026, up 70%–90% from 2025. More than half of year-to-date bookings came from outside its core payer market, supporting management’s diversification strategy.
  • Claims Intelligence grew 17.1%, with NSA dispute initiations up 75% year over year; management expects NSA activity to remain a tailwind. The company also said it expects at least $1.1 billion in revenue in 2027, a year ahead of its prior target.
  • Payment & Revenue Integrity remained below plan as clients shifted from legacy clinical negotiations, more than offsetting growth in newer offerings. Management expects the segment to return to growth in 2027, but noted that bookings typically take time to convert to revenue.
  • Claritev reported a $25.8 million Q3 free cash flow outflow and ended the quarter with $10.1 million of unrestricted cash, $95 million drawn on its revolver, and net leverage of 7.7x. Management expects a strong Q4 cash-flow rebound and reaffirmed its commitment to deleveraging.

Claritev Trading Up 3.0%

NYSE:CTEV traded up $0.69 during mid-day trading on Monday, reaching $23.40. The company’s stock had a trading volume of 137,953 shares, compared to its average volume of 168,301. Claritev has a 12-month low of $11.50 and a 12-month high of $72.67. The stock has a market cap of $396.56 million, a P/E ratio of -1.38 and a beta of 1.05. The firm’s fifty day moving average price is $27.44 and its two-hundred day moving average price is $25.51.

Wall Street Analyst Weigh In

CTEV has been the topic of a number of research reports. Zacks Research raised Claritev from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Citigroup reiterated a “buy” rating and issued a $45.00 price objective (up from $40.00) on shares of Claritev in a research report on Monday, August 10th. Barclays reiterated an “overweight” rating and set a $40.00 price target (up from $28.00) on shares of Claritev in a research report on Thursday, August 20th. Wall Street Zen upgraded Claritev from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, Wells Fargo & Company boosted their price target on Claritev from $22.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.83.

Check Out Our Latest Analysis on Claritev

Insider Transactions at Claritev

In other Claritev news, CEO Travis Dalton purchased 1,950 shares of Claritev stock in a transaction dated Friday, August 28th. The shares were acquired at an average cost of $38.48 per share, with a total value of $75,036.00. Following the completion of the transaction, the chief executive officer owned 52,322 shares in the company, valued at approximately $2,013,350.56. This trade represents a 3.87% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Tiffani Misencik sold 5,812 shares of Claritev stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.81, for a total transaction of $138,383.72. Following the sale, the senior vice president owned 107,917 shares of the company’s stock, valued at $2,569,503.77. The trade was a 5.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have purchased 77,284 shares of company stock valued at $1,927,655 and have sold 23,687 shares valued at $769,078. Corporate insiders own 7.40% of the company’s stock.

About Claritev

(Get Free Report)

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.

Further Reading